Vericel Corporation (VCEL)

$30.92

+1.08 (+3.62%)
Rating:
Recommendation:
Buy
Symbol VCEL
Price $30.92
Beta 1.981
Volume Avg. 0.41M
Market Cap 1.459B
Shares () -
52 Week Range 22.42-60.24
1y Target Est -
DCF Unlevered VCEL DCF ->
DCF Levered VCEL LDCF ->
ROE -9.76% Neutral
ROA -6.72% Neutral
Operating Margin -
Debt / Equity 40.04% Neutral
P/E -
P/B 8.33 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VCEL news


Mr. Dominick Colangelo
Healthcare
Biotechnology
NASDAQ Capital Market

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.